Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associated with younger age, a higher mutational burden, and a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lucía Serrano García, Beatriz Jávega, Antonio Llombart Cussac, María Gión, José Manuel Pérez-García, Javier Cortés, María Leonor Fernández-Murga
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	triple negative breast cancer immunosuppression immunotherapy therapeutic target signaling pathway tumor microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1513421/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
by: Alfonso Cortés, et al.
Published: (2024-12-01)

ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer
by: Hae-Yun Jung, et al.
Published: (2023-12-01)

Construction of the bromodomain-containing protein-associated prognostic model in triple-negative breast cancer
by: Wei Chen, et al.
Published: (2025-01-01)

Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer
by: Desh Deepak Singh, et al.
Published: (2024-12-01)

Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer
by: Shanqi Li, et al.
Published: (2024-03-01)

Functionalized biomimetic nanoparticles loaded with salvianolic acid B for synergistic targeted triple-negative breast cancer treatment
by: Nuo Cheng, et al.
Published: (2025-02-01)

The microenvironment cell index is a novel indicator for the prognosis and therapeutic regimen selection of cancers
by: Xian-Yan Yang, et al.
Published: (2025-01-01)

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities
by: Wen-yu Cai, et al.
Published: (2025-02-01)

Tumor microenvironment and immunotherapy for triple-negative breast cancer
by: Zijie Guo, et al.
Published: (2024-12-01)

Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features
by: Florence Boissière-Michot, et al.
Published: (2024-12-01)

Política cultural, política exterior : balance de la proyección de Cataluña en Francia (siglos XIX y XX)
by: María Llombart Huesca
Published: (2013-03-01)

Política cultural de la Generalitat de Catalunya: cap a una “normalitat” cultural? El Departament de cultura i mitjans de comunicació (1980-1984)
by: Maria Llombart Huesca
Published: (2011-12-01)

Pandora
by: María Llombart Huesca
Published: (2012-10-01)

The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer
by: Zhideng Yan, et al.
Published: (2024-12-01)

RSL3 induces ferroptosis by activating the NF-κB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel
by: Jialin Yuan, et al.
Published: (2025-01-01)

ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer
by: Guanpeng Wang, et al.
Published: (2023-12-01)

Regulation of Oxygen in the Tumor Microenvironment Synergizes with Immunotherapy to Suppress Tumor Progression
by: Shoucheng Wang, et al.
Published: (2024-11-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer
by: Yu-Chia Chen, et al.
Published: (2024-11-01)

Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
by: Chang Cheng, et al.
Published: (2025-01-01)

Functions of double‐negative B cells in autoimmune diseases, infections, and cancers
by: Michael King Yung Chung, et al.
Published: (2023-06-01)

Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression
by: Jian Pang, et al.
Published: (2025-01-01)

Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
by: Ruiliang Chen, et al.
Published: (2024-12-01)

Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience
by: Artur Bocian, et al.
Published: (2024-12-01)

Comprehensive analysis of the metabolomics and transcriptomics uncovers the dysregulated network and potential biomarkers of Triple Negative Breast Cancer
by: Sisi Gong, et al.
Published: (2024-11-01)

Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition
by: Danxiang Chen, et al.
Published: (2024-12-01)

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
by: Jia-xin Qiao, et al.
Published: (2024-12-01)

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
by: Xinyu Ren, et al.
Published: (2025-04-01)

Avant-propos
by: Géraldine Galeote, et al.
Published: (2013-11-01)

Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1
by: Qin Zhu, et al.
Published: (2024-11-01)

Classifications of triple-negative breast cancer: insights and current therapeutic approaches
by: Ziqi Chen, et al.
Published: (2025-02-01)

Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes
by: Cheng C, et al.
Published: (2025-01-01)

Mechanistic exploration of Traditional Chinese Medicine regulation on tumor immune microenvironment in the treatment of triple-negative breast cancer: based on CiteSpace and bioinformatics analysis
by: Dandan Feng, et al.
Published: (2025-01-01)

Advances in the Understanding of the Pathogenesis of Triple‐Negative Breast Cancer
by: Yuhan Liu, et al.
Published: (2024-11-01)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01)

Triple-negative ectopic breast cancer of the male scrotum: a case report
by: Yuhui Nie, et al.
Published: (2024-12-01)

Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer
by: Xu H, et al.
Published: (2024-12-01)

Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq
by: Yulin Shi, et al.
Published: (2025-02-01)

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
by: Huayan Gu, et al.
Published: (2025-02-01)